Annual sales of the 26th homegrown new drug ‘Suganon (evogliptin)’ family that was developed by Dong-A ST has reached ₩30 billion 5 years into its release.

During an interview with Dailypharm, Sung-Woo Lee, the GPM who oversees the marketing of Suganon, said, “Market share of Suganon has been steadily increasing due to its superior efficacy data, such as its strong effect in lowering blood sugar levels and its stable maintenance of glycemic variability, as well as efforts to improve convenience in intake. With our product line-up, expanded indication, and active efforts to expand to the overseas market, we will continue to grow our homegrown new drug.”

◆Last latecomer Sugano

(same@dailypharm.com)